Rapport Therapeutics, Inc. Common Stock

RAPPNASDAQHealthcare● Active

$36.68

+$0.58(+1.61%)

Market Cap$1.3B

P/E Ratio—

52W High$42.269

52W Low$10.505

Avg Volume341K

Open$36.76

Beta0.98

Cash on Hand Financials Revenue

Rapport Therapeutics, Inc. Common Stock (RAPP) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

RAPP · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$490.5M▲ +60.7% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$52.6M

cashAndCashEquivalents

Short-Term Investments

$437.9M

shortTermInvestments

YoY Change vs Prior Year

+60.7%

vs prior fiscal year

Latest Quarter

$476.8M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$490.5MCash on Hand

Total Debt$11.5MTotal Debt

Net Cash / Net Debt+$479.1MNet Cash Position

Cash vs Debt Ratio

Cash 98%Rapport Therapeutics, Inc. Common Stock cash as % of market cap: 36.64%% · MCap $1BDebt 2%

Rapport Therapeutics, Inc. Common Stock has a net cash position of $479.1M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$490.5M − $11.5M = +$479.1M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

RAPP annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

RAPP cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$490.5M+60.7%

Dec 31, 2024FY$305.3M+107.0%

Dec 31, 2023FY$147.5M+373.3%

Dec 31, 2022FY$31.2M—

RAPP cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

RAPP vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Rapport Therapeutics, Inc. Common StockYOU

RAPP

$490.5M$1B36.6%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Rapport Therapeutics, Inc. Common Stock (RAPP) cash on hand as of December 31, 2025 is $490.5M, comprising $52.6M in cash and cash equivalents (CCE) plus $437.9M in short-term investments — reported as Rapport Therapeutics, Inc. Common Stock cash and short-term investments on the balance sheet (10-K filing). Also referred to as Rapport Therapeutics, Inc. Common Stock cash reserves or cash position.

Rapport Therapeutics, Inc. Common Stock annual cash on hand history shows increased +60.7% in 2025: increased +60.7% in 2025. Rapport Therapeutics, Inc. Common Stock cash reserves in 2025 reflect the company's capital allocation strategy.

Rapport Therapeutics, Inc. Common Stock carries total debt of $11.5M against cash of $490.5M, resulting in a net cash position of +$479.1M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

RAPP cash on hand · 5 questions

As of December 31, 2025, Rapport Therapeutics, Inc. Common Stock (RAPP) has $490,539,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $52,645,000 in cash and cash equivalents (CCE) plus $437,894,000 in short-term investments. Latest quarter (March 31, 2026): $476,782,000. Data sourced from the annual 10-K filing via FMP.

RAPP cash on handRAPP cash reservesRAPP cash 2025how much cash does RAPP have

▸ Source: FMP /balance-sheet-statement · US GAAP · Rapport Therapeutics, Inc. Common Stock · Rapport Therapeutics, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025